Richez, V., Gruchet, C., Guidez, S., Fouquet, G., Azais, I., Durand, G., Javaugue, V., Brigaud, A., Plasse, F., Diolez, J., Machet, A., Moya, N., Gardeney, H., Franques, P., Bobin, A., Levy, A., Sabirou, F., Bonnin, A., Dieval, C., Primault, S., Barrier, J., Fleck, E., Bouyier, S., Daras, C., Princet, I., Bauwens, D., Legros, L., Fuzibet, J., Gil, A., Bridoux, F., Avet‐Loiseau, H., & Leleu, X. (n.d.). carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. American journal of hematology, 94(1), E17–E20. http://access.bl.uk/ark:/81055/vdc_100075589672.0x000045